Miraca Life Sciences Announces the Presentation of a Research Poster at the 2014 Meeting of the American Urological Association

Rajal B. Shah, MD, Director of Urologic Pathology for Miraca Life Sciences, presents a recent study on PTEN and ERG Biomarker Interpretation.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Irving, Texas (PRWEB) April 01, 2014

Miraca Life Sciences, the nation’s largest independent anatomical pathology laboratory, is honored to present an abstract at the 2014 Meeting of the American Urological Association (AUA) May 16-21 in Orlando, Florida. Among other results, the study showed that both PTEN and ERG biomarkers demonstrate significant inter- and intra-tumor core staining heterogeneity, suggesting that sampling may affect biomarkers interpretation. Also, ERG overexpression shows strong relationship with PTEN loss, and PTEN loss is significantly associated with Gleason score.

Rajal B. Shah, MD, Director of Urologic Pathology for Miraca Life Sciences, evaluated the heterogeneity of PTEN and ERG biomarkers expression in PCa NBXs setting, and assessed biomarkers staining pattern in reference to cancer cores with highest Gleason score and/or tumor volume to evaluate optimal biomarkers evaluation sampling strategy. ERG and PTEN immunohistochemistry has been shown to be a sensitive and specific approach to detect underlying genetic abnormality and are increasingly analyzed in prostate needle biopsies (NBXs); ERG as a marker of clonality and number of tumor foci and PTEN due to its prognostic relevance.

Prostate cancer (PCa) is typically a multifocal disease. Multifocal PCa is known to exhibit frequent clinical, histologic, and genomic heterogeneity. The dominant (Index) tumor is considered to be biologically the most representative tumor that typically determines clinical behavior. Genomic rearrangements leading to the formation of TMPRSS2-ETS gene fusions and deletion of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) tumor suppressor gene are the two most frequent alterations observed in PCa.

For the complete study, please visit http://www.MiracaLifeSciences.com.

"Miraca has a responsibility to undergo meaningful investigative endeavors to enrich the existing body of scientific knowledge," said Richard Lash, MD, Chief Medical Officer for Miraca Life Sciences. “This research ultimately serves our overriding purpose to ensure that every patient receives the right answer. This research abstract is exemplary of Miraca Life Sciences’ continuing commitment to research and academic excellence.”

Publishing groundbreaking information in high-impact peer-reviewed journals, global symposia, workshops, seminars and courses nationwide, Miraca Life Sciences enhances pathologists’ laboratory and clinical acumen. Miraca Life Sciences’ dedicated group of pathologist-scientists expands pathology’s boundaries through their ideas and discoveries.

About Miraca Life Sciences

Miraca Life Sciences specializes in the development and commercialization of the highest quality academic pathology services, primarily in the fields of dermatology, hematology, gastroenterology and urology. The company’s core team of more than 90 academic-caliber specialists utilizes state-of-the-art pathology laboratories currently headquartered in Irving, Texas, and throughout the United States to serve more than 5,500 patients every day. Through rigorous quality assurance, daily and monthly conferences, and close relationships with clinical partners, Miraca Life Sciences continuously improves diagnostic precision.

About AUA

Founded in 1902, the American Urological Association (AUA) is a premier urologic association, providing invaluable support to the urologic community. Our mission is to promote the highest standards of urological clinical care through education, research and the formulation of health care policy.


Contact